| Cover | 9 Months Ended |
| Sep. 30, 2022 | |
| Cover [Abstract] | |
| Document Type | 6-K |
| Amendment Flag | false |
| Document Period End Date | Sep. 30, 2022 |
| Document Fiscal Period Focus | Q3 |
| Document Fiscal Year Focus | 2022 |
| Current Fiscal Year End Date | --12-31 |
| Entity File Number | 001-36581 |
| Entity Registrant Name | Vascular Biogenics Ltd. |
| Entity Central Index Key | 0001603207 |
| Entity Address, Address Line One | 8 HaSatat St |
| Entity Address, City or Town | Modi’in |
| Entity Address, Country | IL |
| Entity Address, Postal Zip Code | 7178106 |
| Condensed Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
| Current assets: | ||
| Cash and cash equivalents | $ 18,302 | $ 21,986 |
| Short-term bank deposits | 9,076 | 31,164 |
| Other current assets | 148 | 1,697 |
| Total current assets | 27,526 | 54,847 |
| Non-current assets: | ||
| Restricted bank deposits | 360 | 362 |
| Long-term prepaid expenses | 182 | |
| Funds in respect of employee rights upon retirement | 365 | 415 |
| Property, plant and equipment, net | 6,601 | 6,847 |
| Operating lease right-of-use assets | 674 | 2,008 |
| Total non-current assets | 8,000 | 9,814 |
| Total assets | 35,526 | 64,661 |
| Accounts payable and accruals: | ||
| Trade | 1,766 | 4,331 |
| Other | 7,249 | 4,408 |
| Deferred revenue | 658 | |
| Current maturity of operating leases liability | 731 | 529 |
| Total current liabilities | 9,746 | 9,926 |
| Non-current liabilities: | ||
| Liability for employee rights upon retirement | 475 | 546 |
| Operating lease liability | 1,823 | |
| Other non-current liability | 188 | |
| Total non-current liabilities | 475 | 2,557 |
| Total liabilities | 10,221 | 12,483 |
| Ordinary shares subject to possible redemption, as of September 30, 2022 and December 31, 2021, zero and 615,366 shares, respectively, at redemption value (see note 4) | 1,598 | |
| Shareholders’ equity: | ||
| Ordinary shares, NIS 0.01 par value; Authorized as of September 30, 2022 and December 31, 2021, 200,000,000, and 150,000,000 shares, respectively; issued and outstanding as of September 30, 2022 and December 31, 2021 69,750,117 and 68,711,584 shares, respectively (excluding - zero- and 615,366 shares subject to possible redemption, as of September 30, 2022 and December 31, 2021, respectively) | 177 | 171 |
| Additional paid in capital | 316,233 | 309,355 |
| Warrants | 3,127 | |
| Accumulated deficit | (291,105) | (262,073) |
| Total equity | 25,305 | 50,580 |
| Total liabilities and equity | $ 35,526 | $ 64,661 |
| Condensed Consolidated Statements of Financial Position (Unaudited) (Parenthetical) - ₪ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
| Statement of Financial Position [Abstract] | ||
| Shares subject to possible redemption | 0 | 615,366 |
| Common stock, par value | ₪ 0.01 | ₪ 0.01 |
| Common stock, shares authorized | 200,000,000 | 150,000,000 |
| Common stock, shares issued | 69,750,117 | 68,711,584 |
| Common stock, shares outstanding | 69,750,117 | 68,711,584 |
| Condensed Consolidated Statements of Net Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
| Revenue from Contract with Customer [Abstract] | ||||
| Revenues | $ 481 | $ 199 | $ 658 | $ 572 |
| Cost of revenues | (63) | (91) | (152) | (270) |
| Gross profit | 418 | 108 | 506 | 302 |
| Research and development expenses, net | 5,947 | 4,996 | 20,128 | 16,407 |
| General and administrative expenses | 3,746 | 1,625 | 9,831 | 4,779 |
| Operating loss | 9,275 | 6,513 | 29,453 | 20,884 |
| Financial income | (140) | (19) | (491) | (106) |
| Financial expenses | 35 | 8 | 70 | 35 |
| Financial income, net | (105) | (11) | (421) | (71) |
| Net loss and comprehensive loss | $ 9,170 | $ 6,502 | $ 29,032 | $ 20,813 |
| Loss per share (see note 3) | ||||
| Basic and diluted | $ 0.12 | $ 0.09 | $ 0.37 | $ 0.33 |
| Weighted average shares outstanding | ||||
| Basic and diluted | 77,630,238 | 70,298,677 | 77,472,049 | 63,530,781 |
| Condensed Consolidated Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders' Equity (Unaudited) - USD ($) $ in Thousands | Common Stock [Member] | Common Stock [Member] Common Stock Subject to Mandatory Redemption [Member] | Additional Paid-in Capital [Member] | Warrants [Member] | Retained Earnings [Member] | Total | |
| Beginning balance at Dec. 31, 2020 | $ 108 | $ 252,561 | $ 10,401 | $ (232,153) | $ 30,917 | ||
| Beginning balance, shares at Dec. 31, 2020 | 48,187,463 | ||||||
| Net loss | (20,813) | (20,813) | |||||
| Issuance of ordinary shares, net of issuance costs | $ 27 | 30,730 | 30,757 | ||||
| Issuance of ordinary shares, net of issuance costs, shares | 8,871,790 | ||||||
| Exercised warrants | $ 14 | 8,879 | (1,845) | 7,048 | |||
| Exercised warrants, shares | 4,893,838 | ||||||
| Issuance of ordinary shares subject to possible redemption | $ 1,598 | ||||||
| Issuance of ordinary shares subject to possible redemption,shares | 615,366 | ||||||
| Share based compensation | 1,332 | 1,332 | |||||
| Ending balance at Sep. 30, 2021 | $ 149 | $ 1,598 | 293,502 | 8,556 | (252,966) | 19,241 | |
| Ending balance, shares at Sep. 30, 2021 | 61,953,091 | 615,366 | |||||
| Beginning balance at Dec. 31, 2021 | $ 171 | $ 1,598 | 309,355 | 3,127 | (262,073) | 50,580 | |
| Beginning balance, shares at Dec. 31, 2021 | 68,711,584 | 615,366 | |||||
| Net loss | (29,032) | (29,032) | |||||
| Expired warrants | 3,127 | (3,127) | |||||
| Reclassification of redemption shares into ordinary shares | $ 2 | $ (1,598) | 1,596 | 1,598 | |||
| Reclassification of redemption shares into ordinary shares, shares | 615,366 | (615,366) | |||||
| Share based compensation to employees and service provider | [1] | 2,137 | 2,137 | ||||
| Share based compensation to employees and service provider, shares | 34,258 | ||||||
| Employee exercise of stock options | $ 4 | 18 | 22 | ||||
| Share based compensation to employees and service provider, shares | 388,909 | ||||||
| Ending balance at Sep. 30, 2022 | $ 177 | $ 316,233 | $ (291,105) | $ 25,305 | |||
| Ending balance, shares at Sep. 30, 2022 | 69,750,117 | ||||||
| [1]less than one thousand dollars | |||||||
| Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
| Sep. 30, 2022 | Sep. 30, 2021 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $ (29,032) | $ (20,813) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 1,061 | 921 |
| Interest (income) expenses | (20) | (34) |
| Net changes in operating leases | (287) | (33) |
| Interest expenses on finance lease | (2) | |
| Exchange losses on cash and cash equivalents and restricted cash | 133 | 41 |
| Changes in accrued liability for employee rights upon retirement | (21) | (5) |
| Share-based compensation | 2,137 | 1,332 |
| Changes in operating assets and liabilities: | ||
| Decrease in other current assets and long-term prepaid expenses | 1,731 | 547 |
| Decrease in trade receivables | 129 | |
| Increase (decrease) in accounts payable: | ||
| Trade | (2,565) | 370 |
| Other (including other non-current liability) | 2,648 | (228) |
| Decrease in deferred revenue | (658) | (574) |
| Net cash used in operating activities | (24,873) | (18,349) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (810) | (943) |
| Investment in short-term bank deposits | (3,000) | (25,108) |
| Maturity of short-term bank deposits | 25,108 | 17,085 |
| Net cash (used in) provided by investing activities | 21,298 | (8,966) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of ordinary shares and warrants | 22 | 32,959 |
| Issuance costs | (2,202) | |
| Proceeds from issuance of ordinary shares subject to possible redemption | 1,598 | |
| Proceeds from exercised warrants | 7,048 | |
| Finance lease payments | (104) | |
| Net cash provided by financing activities | 22 | 39,299 |
| (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (3,553) | 11,984 |
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD | 22,348 | 13,697 |
| EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (133) | (41) |
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD | 18,662 | 25,640 |
| SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING | ||
| Reclassification of ordinary shares subject to possible redemption into ordinary shares | 1,598 | |
| Right of use assets obtained in exchange for new operating lease liabilities | 271 | |
| Purchase of property and equipment in payables | 98 | |
| Decrease in operating lease right of use and operating lease liabilities resulting from early termination of lease | 11 | |
| RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH REPORTED IN THE STATEMENT OF FINANCIAL POSITION | ||
| Cash and cash equivalents | 18,302 | 25,278 |
| Restricted bank deposits included in non-current assets | 360 | 362 |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | 18,662 | 25,640 |
| SUPPLEMENTARY DISCLOSURE ON CASH FLOWS | ||
| Interest received | 173 | 83 |
| Interest paid | $ 2 | |
| GENERAL | 9 Months Ended |
| Sep. 30, 2022 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| GENERAL | NOTE 1 – GENERAL Vascular Biogenics Ltd. (“VBL” or the “Company”) is a biotechnology company developing targeted medicines for immune-inflammatory diseases. VBL’s lead immunology product candidate, VB-601, is a targeted antibody for immune-inflammatory applications expected to enter a Phase 1 first-in-human trial in the first quarter of 2023, subject to the Company’s ongoing strategic process. The product candidate has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease. On July 19, 2022, VBL announced top-line results from its Phase 3 OVAL clinical trial. The trial did not meet the primary endpoints of achieving a statistically significant improvement in progression-free survival (“PFS”) or overall survival (“OS”) and VBL discontinued the trial. VBL has conducted a strategic review of the ofra-vec program and has ceased further development of ofra-vec in all indications. As these results are considered a triggering event, VBL performed an impairment test on all of its assets in the third quarter of 2022. The Company concluded that the value of its gene therapy manufacturing facility is in excess of its carrying value and therefore is not subject to impairment. However, there can be no assurance that the Company will be successful in its efforts to monetize the manufacturing facility, which may lead to an impairment of these assets in a future period. Upon evaluation of the remaining assets and liabilities, (i) VBL wrote off all long term prepaids assets, (ii) recorded severance provisions (including additional termination benefits) for the remaining full time employees, (iii) modified the term of the lease right-of- use assets and liabilities due to reassessment of exercise of the renewal option and reduced the remaining period from 4.5 18 In August 2022, VBL announced an organizational streamlining designed to reduce operating expenses and preserve capital and to date, has reduced its workforce by approximately 48 In August 2022, VBL also received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC, or Nasdaq, notifying that the Company’s listed securities did not maintain the minimum bid price requirement of $ 1.00 1.00 In August 2022, VBL received $ 1.1 Since inception, VBL has incurred significant losses, and it expects to continue to incur significant expenses and losses for at least the next several years. As of September 30, 2022, VBL had an accumulated deficit of $ 291.1 million and cash, cash equivalents, short-term bank deposits and restricted bank deposits of $ 27.7 million. Based on its current cash resources, and successful implementation of its reduction in workforce, VBL believes its current cash will be sufficient to fund estimated operating expenses and capital expenditure requirements for at least 12 months from the date of the filing of these financial statements. VBL is undertaking a review of its strategic options and any transaction resulting from such review may impact this projection. Further, its losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of its clinical trials, the receipt of payments under any future collaboration agreements it may enter into, its expenditures on other research and development activities, as well as any strategic options it may pursue. VBL may seek to raise more capital to pursue additional activities, including through a combination of private and public equity offerings, debt, government grants, strategic collaborations and licensing arrangements. Additional financing may not be available when VBL needs it or may not be available on terms that are favorable to VBL. If VBL is unable to raise additional funds through equity or debt financings or through strategic alliances when needed, or conclude any strategic transaction for its assets to maximize shareholder value, it may be required to delay, limit, reduce or terminate its product development efforts or cease operations altogether. Failure to obtain additional financing will have a material, adverse impact on the Company’s business operations and there can be no assurance that VBL will be able to obtain the needed financing to achieve its goals on acceptable terms or at all. |
| BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS | 9 Months Ended |
| Sep. 30, 2022 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS | NOTE 2 – BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS The accompanying unaudited condensed consolidated financial statements of VBL have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for the fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, VBL Inc. (a U.S.-based subsidiary). These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements in the Annual Report on Form 20-F for the year ended December 31, 2021, filed by VBL with the U.S. Securities and Exchange Commission (the “Commission”) on March 23, 2022. The comparative balance sheet at December 31, 2021 has been derived from the audited financial statements at that date. |
| SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
| Sep. 30, 2022 | |
| Accounting Policies [Abstract] | |
| SIGNIFICANT ACCOUNTING POLICIES | NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES The accounting policies and calculation methods applied in the preparation of the condensed consolidated interim financial statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2021 and for the year then ended. Recently issued accounting pronouncements In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, “Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” “Reference Rate Reform (Topic 848) - Scope.” In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities About Government Assistance.” ASU 2021-10 requires disclosures about transactions with a government that have been accounted for by a grant or contribution accounting model to increase transparency about the types of transactions, the accounting for the transactions, and the effect on the financial statements. The ASU is an annual disclosure effective for fiscal years beginning after December 15, 2021 and will be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements and related disclosures but does not believe there will be a material impact. Net Loss Per Share VBL complies with accounting and disclosure requirements of FASB Accounting Standards Codification (“ASC”) Topic 260, “Earnings Per Share.” Accretion associated with the ordinary shares subject to possible redemption is excluded from loss per ordinary share. Potentially dilutive securities have been excluded from VBL’s computation of net loss per share as such securities would have been anti-dilutive. There were 10,452,173 ordinary shares underlying outstanding options, RSUs and warrants at September 30, 2022, and 17,202,734 ordinary shares underlying outstanding options and warrants at September 30, 2021. |
| SHAREHOLDERS’ EQUITY | 9 Months Ended |
| Sep. 30, 2022 | |
| Equity [Abstract] | |
| SHAREHOLDERS’ EQUITY | NOTE 4 – SHAREHOLDERS’ EQUITY a. On February 11, 2022, VBL entered into an Open Market Sale Agreement SM 0.01 50.0 b. Effective February 13, 2022, the board of directors of VBL approved the adoption of the Inducement Plan (2022) to reserve an additional two million ( 2,000,000 0.01 c. In February 2022, the 615,366 |
| REVENUE | 9 Months Ended |
| Sep. 30, 2022 | |
| Revenue from Contract with Customer [Abstract] | |
| REVENUE | NOTE 5 – REVENUE The revenues recognized for the nine months ended September 30, 2022 comprise revenues from the NanoCarrier License. The revenues are recognized according to ASC 606, “ Revenues from Contracts with Customers.” VBL identified two performance obligations in the NanoCarrier License: (1) Grant of the license and use of its intellectual property; and (2) VBL’s participation and consulting assistance services. In addition, there was a potential performance obligation regarding future manufacturing. In September 2022, the NanoCarrier License was terminated. As VBL does not expect to generate additional revenues from the achievement of new milestones or royalties under the NanoCarrier License, VBL expensed the remaining deferred revenue. Accordingly, during the nine months ended September 30, 2022, VBL recognized revenue of $ 0.7 million. |
| SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
| Sep. 30, 2022 | |
| Accounting Policies [Abstract] | |
| Recently issued accounting pronouncements | Recently issued accounting pronouncements In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, “Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” “Reference Rate Reform (Topic 848) - Scope.” In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities About Government Assistance.” ASU 2021-10 requires disclosures about transactions with a government that have been accounted for by a grant or contribution accounting model to increase transparency about the types of transactions, the accounting for the transactions, and the effect on the financial statements. The ASU is an annual disclosure effective for fiscal years beginning after December 15, 2021 and will be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements and related disclosures but does not believe there will be a material impact. |
| Net Loss Per Share | Net Loss Per Share VBL complies with accounting and disclosure requirements of FASB Accounting Standards Codification (“ASC”) Topic 260, “Earnings Per Share.” Accretion associated with the ordinary shares subject to possible redemption is excluded from loss per ordinary share. Potentially dilutive securities have been excluded from VBL’s computation of net loss per share as such securities would have been anti-dilutive. There were 10,452,173 ordinary shares underlying outstanding options, RSUs and warrants at September 30, 2022, and 17,202,734 ordinary shares underlying outstanding options and warrants at September 30, 2021. |
| GENERAL (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | ||||
| Aug. 31, 2022 | Sep. 30, 2022 | Aug. 02, 2022 | Jul. 19, 2022 | Dec. 31, 2021 | |
| Reduction in percentage of workforce | 48% | ||||
| Retained Earnings (Accumulated Deficit) | $ 291,105 | $ 262,073 | |||
| Cash, Cash Equivalents, and Short-Term Investments | $ 27,700 | ||||
| Nasdaq Stock Market LLC [Member] | |||||
| Minimum bid price, per share | $ 1 | ||||
| Closing bid price, per share | $ 1 | ||||
| European Innovation Council [Member] | |||||
| Proceeds from debt | $ 1,100 | ||||
| Maximum [Member] | |||||
| Lease period | 4 years 6 months | ||||
| Minimum [Member] | |||||
| Lease period | 18 years |
| SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares | 9 Months Ended | |
| Sep. 30, 2022 | Sep. 30, 2021 | |
| Options and Warrants [Member] | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 10,452,173 | 17,202,734 |
| SHAREHOLDERS’ EQUITY (Details Narrative) $ in Thousands | 9 Months Ended | |||||||
| Feb. 13, 2022 ₪ / shares shares | Feb. 11, 2022 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 ₪ / shares shares | Feb. 28, 2022 shares | Feb. 11, 2022 ₪ / shares | Dec. 31, 2021 ₪ / shares shares | |
| Subsidiary, Sale of Stock [Line Items] | ||||||||
| Common stock, par value | ₪ 0.01 | ₪ 0.01 | ||||||
| Proceeds from issuance of ordinary shares and warrants | $ | $ 22 | $ 32,959 | ||||||
| Subject to possible redemption | shares | 0 | 615,366 | 615,366 | |||||
| Board of Directors [Member] | Inducement Plan 2022 [Member] | ||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||
| Common stock, par value | ₪ 0.01 | |||||||
| Number of shares issued | shares | 2,000,000 | |||||||
| Share Purchase Agreement [Member] | At The Market [Member] | ||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||
| Common stock, par value | ₪ 0.01 | |||||||
| Proceeds from issuance of ordinary shares and warrants | $ | $ 50,000 | |||||||
| REVENUE (Details Narrative) $ in Millions | 9 Months Ended |
| Sep. 30, 2022 USD ($) | |
| License [Member] | |
| Disaggregation of Revenue [Line Items] | |
| Contract with Customer, Liability, Revenue Recognized | $ 0.7 |
